Research Articles | Page 5 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study Jul 2020 Leukemia Research Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis Jun 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Raising the bar for lower-risk myelodysplastic syndromes Apr 2023 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Eat and be healthy: nutritional status in myelodysplastic syndromes Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents Oct 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience Nov 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)